Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma

This study reports results from the prespecified health-related quality of life (HRQoL) and neurological deterioration-free survival (NDFS) exploratory analysis.

Source: European Journal of Cancer - February 16, 2021 Category: Cancer & Oncology Authors: Paul M.J. Clement, Linda Dirven, Marica Eoli, Juan M. Sepulveda-Sanchez, Annemiek M.E. Walenkamp, Jean S. Frenel, Enrico Franceschi, Michael Weller, Olivier Chinot, Filip Y.F.L. De Vos, Nicolas Whenham, Paul Sanghera, Jim Looman, Madan G. Kundu, Jan Peter Tags: Original Research Source Type: research